Tests a PSMA PET scan in people with advanced kidney cancer
Tests a PSMA PET scan to find spread of advanced kidney cancer in adults.
Key facts
- Who runs it
- Xijing Hospital
- Where
- Lanzhou, Weinan, Xi'an, Xianyang, Xining, Yan’an, and Yinchuan, ChinaSee the 9 sites
- Trial code
- Registry title
- 68Ga-PSMA PET in the Renal Cell Carcinoma
- Status
- Recruiting
- People taking part
- 300 people, planned
- Started
- 1 Jun 2021
- Expected to end
- 1 Dec 2027
- Type of study
- Interventional
- Treatments tested
- PSMA PET
- Record updated
- 11 March 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with advanced kidney cancer (renal cell carcinoma), stage III or IV, whose CT scan showed suspicious spread. It tests a 68Ga-PSMA PET scan.
- Age
- 18 to 90 years
- Sex
- All sexes can join.
- Disease stage
- Renal cell carcinoma, 2017 AJCC TNM stage III or IV. Contrast-enhanced CT found suspicious metastases.
Main reasons for not taking part
- Cannot lie flat during the PET/CT scan
- Contraindications to 68Ga PSMA ligands
- Another malignant tumor in the past two years
- Impaired kidney function or hemodialysis in progress
- Known peripheral or central venous problems
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- 2017 AJCC renal cell carcinoma TNM stage III, IV lesions
- In contrast-enhanced CT staging, suspicious metastases were found
- There were no known peripheral or central venous problems
- 68Ga PSMA PET / CT imaging can be performed within 6 weeks after the diagnosis of renal cell carcinoma
- Signed the informed consent form of voluntary participation in clinical trials
Who cannot take part
- In the past two years, there was a history of other malignant tumors, or according to the doctor's research judgment, complications may occur and affect the normal operation of the test
- Age ≤ 18 years old
- Can't stand lying flat in PET / CT examination
- There are contraindications for 68Ga PSMA ligands
- Renal function is impaired or hemodialysis is in progress
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 90 years old?
Where in China
- The First Hospital of Lanzhou UniversityLanzhou, ChinaContact: Wei ZhangTaking people
- Weinan Central HospitalWeinan, ChinaContact: Weihong Zhao, MD.Taking people
- Shaanxi provincial people's hospitalXi'an, ChinaContact: Yi Sun, MD.Taking people
- Xijing 986 HospitalXi'an, ChinaContact: Wuhe Zhang, MD.Taking people
- Xijing hospitalXi'an, ChinaContact: Yanyan JiaTaking people
- The Second Affiliated Hospital of Shaanxi University of Chinese MedicineXianyang, ChinaContact: Wei Zheng, MD.Taking people
- Qinghai university affiliated hospitalXining, ChinaContact: Guojun Chen, MD.Taking people
- Affiliated Hospital of Yan'an UniversityYan’an, ChinaContact: Jixue Gao, MD.Taking people
- General Hospital of Ningxia Medical UniversityYinchuan, ChinaContact: Zhiyong Lv, MD.Taking people
About the trial
What the trial wants to find out
The primary research purpose is to evaluate the diagnostic efficacy of 68Ga-PSMA PET in metastatic lesions of locally advanced and advanced renal cell carcinoma, and to compare with that of enhanced CT. The second purpose is to evaluate whether 68Ga-PSMA PET can change the treatment decision of patients with locally advanced and advanced renal cell carcinoma
The group in the trial
- PSMA PET ArmTreatment being tested
The PSMA PET arm received PSMA PET and enhanced CT at the same time in the diagnosis of the patients with suspected renal cancer.
Treatment: PSMA PET
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Prospective, Multicenter Study of Diagnostic Efficiency of 68Ga-PSMA PET in the Patients With Locally Advanced and Advanced Renal Cell Carcinoma
- Plain-language title
- Tests a PSMA PET scan in people with advanced kidney cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT04987086, who can take part
- Record updated
- 11 March 2026